Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.
Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.
Experts reflect on the mixed enthusiasm for concurrent liquid and tissue testing, addressing insurance coverage concerns and the importance of shortening turnaround time, while highlighting efforts to make comprehensive testing the default in the community.
A comprehensive study on the association between the availability of molecular genotyping results and overall survival in advanced non-squamous, non-small cell lung cancer patients, shedding light on the importance of timely and concurrent testing.